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I - INTRODUCTION 
 
Muscle wasting is a serious affliction commonly found 
in  aging  individuals.  It  results  from  the  combined 
effects of muscle atrophy as well as muscle cell death, 
leading to an overall loss of muscle mass and a decrease 
in muscle strength [1, 2]. The results of muscle wasting 
are  often  debilitating  and  are  associated  with  an 
increased  risk  of  mortality.  In  the  elderly  population, 
muscle wasting may be found in both acute (cachectic) 
and  chronic  (sarcopenic)  forms.  These  two  diseased 
states,  though  highly  interconnected,  represent  two 
distinct conditions. Whereas cachexia is only found to 
develop in the presence of an overlying inflammatory 
condition,  sarcopenia  is  an  age-dependent  geriatric 
syndrome that can develop in the absence of any other 
apparent  pre-existing  conditions  (Figure  1)  [1,  2]. 
Sarcopenia is associated with a gradual loss of muscle, 
in contrast to the rapid atrophy associated with cachexia 
[1]. In some patients, cachexia may lead to the onset of 
sarcopenia, inducing a state known as cachexia-related 
sarcopenia [1, 3]. Furthermore, there may be differences 
in  the  underlying  molecular  mechanisms  of  the  two 
disease states. For example, whereas the importance of 
ubiquitin-mediated  degradation  is  well  established  in 
cachexia,  there  is  conflicting  evidence  for  its  role  in 
sarcopenia, suggesting that the proteasomal degradation 
pathway may play a lesser role in age-related muscle 
wasting [4]. The existence of sarcopenia in the absence 
of a primary trigger, as well as the more gradual muscle 
atrophy that is not associated with an upregulation in 
ubiquitin-mediated  degradation,  distinguishes  it  from 
cachexia.  However,  the  ability  of  cachexia  to  induce 
sarcopenia  underscores  the  potentially  overlapping 
molecular  mechanisms  of  the  two  syndromes.  Both 
result in similar changes in the overall metabolic state 
of muscle fibers, leading to atrophy, and the molecular 
mechanisms  leading  to  this  state  may,  in  fact,  share 
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certain common pathways [1, 5]. Indeed, studies have 
implicated  inflammatory  cytokines  as  important 
humoral factors in the pathology of both sarcopenic and 
cachectic muscle wasting (Figure 2). 
 
In  this  review  we  will  briefly  describe  the  molecular 
mechanisms that lead to both cachectic and sarcopenic 
muscle  wasting,  focusing  on  the  shared  role  of 
inflammatory  cytokines  in  both  syndromes. 
Specifically,  we  will  highlight  the  importance  of 
cytokines, such as tumor necrosis factor α (TNFα), as a 
mediator of muscle wasting and as a therapeutic target 
for  the  treatment  of  both  sarcopenia  and  cachexia. 
Although  recent  attempts  to  target  key  players  in  the 
TNFα  signaling  pathway  have  proven  ineffective  [6-
10],  several  studies  have  indicated  that  downstream 
players could represent better targets to combat muscle  
wasting.  One  of  these  players  is  the  inducible  nitric 
oxide synthase (iNOS) enzyme, which is produced by 
many cell types, including muscle fiber, in response to 
TNFα  leading  to  nitric  oxide  (NO)  production  and 
muscle  wasting  [11,  12].  Growing  evidence  suggests 
that  the  iNOS/NO  pathway  is  involved  in  both 
sarcopenia  and  cachexia-induced  muscle  wasting  [11-
14]. Here, we will summarize the current knowledge of 
the  role  of  this  pathway  in  muscle  atrophy  and 
emphasize  its  potential  as  a  target  for  future  drug 
development. 
 
II - SARCOPENIA 
 
The  term  sarcopenia—a  combination  of  the  Greek 
words  sarx,  meaning  ―flesh‖,  and  penia,  meaing 
―loss‖—was first coined by Dr. Rosenberg to describe 
the  phenomenon  whereby  aging  individuals  would 
exhibit a gradual loss of  muscle mass [15]. Over the 
years,  several  clinical  definitions  of  sarcopenia  have 
been proposed [2, 3, 16]. The most recent one defines 
sarcopenia  as  the  ―age-associated  loss  of  skeletal 
muscle mass and function‖ [3]. This loss of muscle is 
considered one of the most dramatic effects of aging on 
the quality of life of aged individuals [15]. Sarcopenia is 
a highly prevalent syndrome affecting a large portion of 
the  geriatric  population.  It  is  estimated  that  25%  of 
individuals over the age of 64 suffer from sarcopenia, 
and that percentage is doubled in individuals over the 
age  of  80  [17,  18].  Starting  at  age  30,  muscle  mass 
begins to  decline at an average rate of 1-2% per year
Figure  1:  Inflammatory-induced  sarcopenia  vs.  cachexia.  Sarcopenia  and  cachexia 
represent two distinct diseased states, though both can result from an imbalance in the body’s 
inflammatory  mechanisms.  Whereas  sarcopenia  (blue)  results  from  chronic  inflammation 
associated  with  age,  cachexia  (orange)  results  from  inflammation  associated  with  a  primary 
disease (e.g. cancer, AIDS, and sepsis). Although resulting from different overlying conditions, 
both sarcopenia and cachexia result in muscle atrophy and loss. The dramatic loss of skeletal 
muscle tissue, occurring gradually in sarcopenia and acutely in cachexia, leads to disability and 
increased mortality. 
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 [19]. This gradual loss of muscle eventually leads to 
increased frailty, resulting in disability and a dramatic 
increase  in  the  rate  of  mortality  [20].  Currently,  the 
most effective way to prevent sarcopenic muscle loss is 
through  strength  training  exercise  combined  with  or 
without amino acid nutritional supplementation [21-23]. 
However, keeping to a regimented, intensive exercise 
program may be too difficult or undesirable for many 
elderly patients [23]. Therefore, it is still important to 
develop drug-therapies for the treatment of sarcopenia. 
To date, pharmacological therapies for sarcopenia have 
been  met  with  limited  success  [21,  23].  Thus,  it  is 
important  to  elucidate  the  molecular  mechanism  of 
sarcopenia in order to identify new therapeutic targets. 
 
A - Causes of sarcopenia 
 
Several factors associated with aging are believed to 
contribute  to  the  onset  and  progression  of  sarcopenia 
(Figure 2). Decreased physical activity, common among 
aged individuals, has been identified as a risk factor for 
the development of sarcopenia [24]. Additionally, a lack 
of  adequate  amino  acid  content  in  the  diets  of  most 
elderly  individuals,  compounded  by  the  inherent 
undernutrition associated with age, is believed to lead to 
a reduction in anabolic activity that likely contributes to 
the progressive loss of muscle mass [25, 26]. However, 
sarcopenia is also associated with obesity and insulin 
resistance  [26,  27].  It  has  been  suggested  that  the 
hyperactivity  of  energy-sensing  pathways  (such  as 
mTOR) induces muscle loss as a result of a negative 
feedback  loop  that  causes  secondary  resistance  to 
growth  stimuli  [28].  This  may  explain  why  caloric 
restriction,  without  causing  malnutrition,  prevents 
sarcopenic  muscle  wasting  in  rhesus  monkeys  [29]. 
Besides  these  life-style  factors,  other  biological 
Figure 2: Underlying mechanisms involved in muscle wasting diseases. Despite the fact 
that  both  diseases  result  in  muscle  wasting,  the  underlying  causes  of  sarcopenia  (blue)  and 
cachexia  (orange)  are  distinct.  Sarcopenia  arises  from  a  multitude  of  factors,  including  (1) 
decreased amino acid intake, (2) diminished physical activity, (3) loss of motor neurons with age, 
and  (4)  a  decline  in  anabolic  stimulating  hormones.  Cachexia,  in  contrast,  results  from  the 
physiological changes that occur during the progression of other chronic inflammatory illnesses. In 
cancer, the REE (Resting Energy Expenditure) is known to increase, pushing the overall energy 
state towards a negative energy balance. This effect is further exacerbated (dashed arrow) by 
anorexia, which, although not a direct cause of cachectic muscle loss, often accompanies cachexia 
and  contributes  towards  the  overall  negative  energy  balance.  Finally,  several  host  humoral 
factors, such as glucocorticoids and angiotensin II, are known to induce muscle wasting, affecting 
the overall metabolic state by either by augmenting catabolism, decreasing anabolism, or both. 
Furthermore,  the  tumor  factor  PIF  (Proteolysis  Inducing  Factor)  has  also  been  implicated  in 
murine models of cancer cachexia, though its role in human cachexia has yet to be confirmed. In 
addition  to  the  above  factors,  inflammatory  cytokines  are  believed  to  play  a  key  role  in  the 
pathology of both sarcopenia and cachexia. As a uniquely common cause of both diseased states, 
inflammatory cytokines represent an enticing target for the development of drug therapies. 
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sarcopenia [13, 24, 30-40]. The progressive decline of 
motor  neuron  function  during  aging  leads  to 
denervation of muscle fibers, which can result in muscle 
mass loss  (Figure 2) [32, 33]. It has also been found 
that declining hormone levels may play a role in age-
related  muscle  atrophy.  In  men,  low  testosterone  and 
vitamin  D  levels  are  considered  risk  factors  for  the 
development of sarcopenia [24]. Furthermore, there is 
an  age-related  decline  in  serum  levels  of  growth 
hormone (GH) and insulin-like growth factor-1 (IGF-1). 
Loss  of  these  anabolic-stimulating  hormones  may 
contribute to the progression of muscle atrophy (Figure 
2) [35, 36]. Another known cause of sarcopenia is the 
age-related  increase  in  proinflammatory  cytokines,  a 
process  known  as  inflamm-aging  [41].  The 
proinflammatory state affects the metabolic balance in 
muscle fibers, leading to muscle atrophy and apoptosis 
(Figure 2) [42]. 
 
B - Role of inflammatory cytokines in sarcopenia 
 
Several studies have implicated elevated levels of two 
cytokines,  interleukin-6  (IL-6)  and  TNFα,  in  the 
development  of  sarcopenia.  Studies  of  IL-6  plasma 
levels in the elderly community found that individuals 
with higher circulating IL-6 levels were more likely to 
suffer from fatigue and disability, suggesting that IL-6 
may be involved in the age-related decline in muscle 
function [37, 38]. IL-6 was later found to correlate with 
lower muscle mass and strength, further implicating it 
in the progression of sarcopenia [39]. In the same study, 
TNFα plasma concentration was also found to correlate 
with lower muscle mass and strength, suggesting that 
TNFα  may  be  another  humoral  mediator  of  muscle 
atrophy  in  the  aged  population  [39].  Indeed,  in  their 
clinical study of 2,177 men and women, Schaap et al. 
found a correlation between increased serum levels of 
TNFα and decreased muscle mass and strength over a 5-
year period [43]. TNFα is believed to induce muscle cell 
apoptosis, which may partially account for this geriatric 
muscle loss [44]. The increase of IL-6 and TNFα serum 
levels is indicative of an over-all proinflammatory state 
that develops during the aging process. The activation 
of the inflamm-aging process is believed to be the result 
of an upregulation of the transcription factor NF-κB, an 
important regulator of the innate immune response [42]. 
This  constitutive  and  elevated  activity  of  NF-κB 
associated with aging has been suggested to be one of 
the  underlying  causes  of  sarcopenia  [45,  46].  As  an 
important mediator of NF-κB induced muscle wasting 
[12, 47], it is likely that iNOS plays an important role in 
the pathology of sarcopenia. Indeed, an in vivo study 
comparing  the  muscle  tissue  of  young  and  old  mice 
found  that  iNOS  was  upregulated  in  elderly  murine 
muscle,  implicating  iNOS  as  a  key  effecter  of 
sarcopenic muscle loss [13]. 
 
III – CACHEXIA 
 
Cachexia is a fatal syndrome that develops in patients 
with  chronic  inflammatory  conditions  such  as  cancer, 
AIDS, and sepsis [48, 49]. Cachexia is characterized by 
a severe wasting (up to 75%) of skeletal muscle tissue 
[50]. This dramatic loss of muscle mass leads to loss of 
motor function, an overall decrease in the quality of life, 
and a reduced survival rate (Figure 1) [49]. It has been 
estimated that 2% of the general population is afflicted 
with  early-stage  cachexia  (defined  as  weight  loss  in 
association with a chronic disease). Of these 2%, it is 
unknown  how  many  progress  to  late  stage  cachexia 
[51].  However,  it  is  important  to  note,  that  cachexia 
mostly  affects  patients  with  chronic  diseases.  Within 
this  subpopulation,  the  prevalence  of  early  stage 
cachexia can reach as high as 36%, as is the case for 
chronic obstructive pulmonary disease (COPD) [51]. It 
has  been  shown  that  up  to  22%  of  all  cancer-related 
deaths are directly caused by cachexia, rather than the 
primary malignancy [52]. Death is frequently caused by 
extensive wasting of the respiratory muscles, leading to 
hypostatic  pneumonia  [53,  54].  Cachexia  is  often 
accompanied  by  loss  of  adipose  tissue,  anemia,  and 
anorexia,  all  of  which  further  contribute  to  its 
detrimental effects [48, 49]. Despite the importance of 
muscle wasting syndrome in the pathology of several 
prevalent diseases, very few treatment options exist for 
patients with cachexia. 
 
A - Causes of cachexia 
 
One  of  the  main  characteristics  of  cachexia-related 
muscle  atrophy  is  that,  unlike  starvation-induced 
atrophy,  it  cannot  be  reversed  with  nutritional 
supplements [48, 55, 56]. This indicates that complex 
metabolic changes have occurred in patients undergoing 
muscle wasting. In an attempt to better understand the 
disease, and to identify potential drug targets for future 
therapy, many of the underlying causes of cachexia are 
currently under investigation (Figure 2). Changes in the 
body’s energy balance are believed to contribute to the 
overall catabolic state found in cachexia. Although not 
believed to be a direct cause of cachectic muscle loss, 
anorexia often accompanies cachexia and contributes to 
the  onset  of  this  syndrome  [48,  57].  Moreover,  the 
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often  found  in  cancer  patients  may  contribute  to  the 
overall decline in the energy balance of skeletal muscle 
tissues [48]. In addition to the general changes in the 
metabolic energy state, several humoral factors are also 
believed to trigger muscle atrophy and loss. Proteolysis 
Inducing Factor (PIF), glucocorticoids, and angiotensin 
II have all been implicated in the progression of cancer 
cachexia  [48].  Furthermore,  it  is  believed  that  an 
increase in circulating inflammatory cytokine levels is 
one of the main causes of cachexia. Cytokines that have 
been implicated in the development of cachexia include 
IL-6, IL-1, TNFα, and interferon-gamma (IFN-γ) [49, 
58]. 
 
B - The role of IL-6 and IL-1 in cachexia  
 
IL-6 has been connected to cachexia by both clinical 
and in vivo studies. An investigation into the levels of 
IL-6  in  terminally  ill  cachectic  cancer  patients  found 
that  IL-6  levels  were  dramatically  elevated  one  week 
prior  to  death  [59].  A  study  of  APC
Min/+  mice—an 
established murine model for cancer cachexia in which 
a germline mutation in the adenomatous polyposis coli 
(APC) gene results in the development of colon cancer 
[60]—found  a  severe  wasting  of  the  gastrocnemius 
muscle  that  correlated  with  a  10-fold  increase  in 
circulating  IL-6  levels  when  compared  to  wild-type 
mice [61]. Furthermore, the genetic ablation of IL-6 in 
these  mice  prevented  the  onset  of  muscle  wasting 
symptoms. The cachectic symptoms were rescued when 
recombinant IL-6 was over-expressed using a plasmid 
vector in the IL-6 -/- mice, confirming that IL-6 was 
necessary for the development of muscle wasting [61]. 
Interestingly,  IL-6  over-expression  did  not  induce 
muscle wasting in non-tumor bearing mice, indicating 
that  IL-6  may  cause  muscle  wasting  indirectly  by 
increasing tumor burden [48, 61]. IL-6 has also been 
shown  to  increase  the  expression  and  activity  of 
cathepsins  (B  and  L)  and  ubiquitin,  leading  to  the 
activation of the lysosomal and proteasomal proteolytic 
cleavage pathways, respectively [62, 63]. IL-6 signaling 
involves the STAT-3 pathway, but it is unclear whether 
this  pathway  plays  a  role  in  IL-6-induced  muscle 
wasting  [61].  The  effects  of  IL-6  in  vivo  may  be 
augmented  by  the  secretion  of  IL-1,  which  has  been 
shown to increase the expression of IL-6 by colon-26 
carcinoma cells [64, 65]. IL-1 has also been implicated 
in other models of cachexia. Administering IL-1 to rats 
was found to induce wasting in the peripheral muscles, 
and  IL-1  receptor  antagonists  prevent  sepsis-induced 
cachexia  in  rats  by  recovering  protein  synthesis  [66, 
67]. These results show that IL-1 is both sufficient and 
necessary for the induction of cachexia in rat models, 
but the role of IL-1 in human cachexia remains unclear.  
 
C - The role of TNFα/IFN-γ in cachexia 
 
Several  animal  models  for  cachexia  have  shown  that 
TNFα is one of the main cytokines that triggers muscle 
wasting.  Mice  implanted  with  Chinese  hamster  ovary 
(CHO)  cells  transfected  with  a  human  TNFα  vector 
develop cachexia and die sooner than mice implanted 
with CHO cells transfected with a control vector alone 
[68].  Furthermore,  transplantation  of  Lewis  lung 
carcinoma  cells  into  transgenic  mice  expressing  a 
soluble TNFα receptor protein showed reduced muscle 
wasting, even though TNFα serum levels were found to 
remain  constant.  This  demonstrated  that  TNFα  was 
necessary for the development of cachexia in this model 
[69]. TNFα is known to mediate its effects through the 
transcription factor NF-κB, which is responsible for the 
regulation of a wide variety of genes [70]. Two of the 
main  mechanisms  by  which  NF-κB  induces  muscle 
wasting are through the upregulation of the ubiquitin-
proteasome pathway (due to the increased expression of 
the  muscle  specific  ubiquitin-ligase  MuRF1)  and 
through an increase in the expression of iNOS, leading 
to  oxidative  stress  [10-12,  71,  72].  Treatment  with 
TNFα alone, however, is not always sufficient to induce 
a  major  cachectic  response.  It  has  been  shown  that 
TNFα  when  administered  with  the  cytokine  IFN-γ, 
triggers a more pronounced cachectic response than if it 
was  administered  alone  [72,  73].  IFN-γ  was  first 
identified  as  an  important  humoral  factor  in  the 
development of cachexia by Matthys et al., who showed 
that  injecting  mice  with  IFN-γ-producing  CHO  cells 
induced muscle wasting. The development of cachexia 
in  mice  was  dependent  on  the  presence  of  a  tumor, 
indicating that IFN-γ likely mediates its cachectic effect 
in concert with other cytokines, such as TNFα [74].  
 
D - The importance of TNFα in human cachexia  
 
Although  the  role  of  the  TNFα  signaling  pathway  in 
cachectic muscle wasting has been clearly demonstrated 
both in vitro and in vivo [68, 69, 75], its role in human 
cachexia, and by extension its potential as a therapeutic 
target,  was  previously  uncertain  [48,  58].  However, 
recent  evidence  has  clearly  shown  that  the  TNFα 
pathway  is  a  significant  part  of  human  cachexia 
pathology.  In  a  study  of  skeletal  muscle  from  cancer 
and  AIDS  patients  suffering  from  cachexia, 
Ramamoorthy et al. analyzed the rectus abdominis and 
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iNOS,  and  several  proteins  important  for  muscle 
differentiation  and  maintenance,  including  Jun-D, 
myogenin, myosin, and CKM (muscle creatine kinase). 
They found that patients with cachexia had consistently 
higher levels of TNFα mRNA and protein. Furthermore, 
they found that the level of active forms of the TNFα 
receptor was significantly increased in patients suffering 
from cachexia. In addition, the expression of both iNOS 
mRNA and protein was found to be upregulated in the 
muscle tissue of cachectic patients, suggesting a role for 
the  iNOS/NO  pathway  in  TNFα-induced  muscle 
wasting in humans [14]. These results clearly indicate 
that  interfering  with  TNFα-signaling  could  be  an 
effective therapeutic strategy to combat cachexia.  
 
E - Targeting the TNFα pathway: several attempts but 
little success 
 
Several  drugs  targeting  TNFα  signaling  have  been 
investigated for their potential use in the treatment of 
cachexia.  Unfortunately,  they  have  all  proven  to  be 
ineffective therapeutics. Thalidomide, a drug that both 
augments TNFα mRNA degradation and inhibits NF-κB 
[50], was found to be successful in preventing the loss 
of lean body weight in cachectic patients, but failed to 
improve  quality  of  life  and  survival  rates  [6,  7].    In 
addition, thalidomide has been associated with severe 
side  effects,  such  as  teratogenesis,  deep  vein 
thrombosis, and peripheral neuropathy [6, 7]. Two other 
drugs, Etanercept (a dimeric fusion protein commonly 
used  for  the  treatment  of  rhematoid  arthritis)  and 
infliximab (a monoclonal antibody against TNFα), have 
also  been  met  with  limited  success  in  clinical  trials, 
showing  no  improvement  in  cancer  patients  suffering 
from cachexia [8, 9]. To our knowledge, there are no 
drugs that target TNFα currently in development for the 
treatment  of  sarcopenia.  Furthermore,  the  use  of 
pharmacological  intervention  for  the  treatment  of 
sarcopenia has also been met with limited success [21, 
23].  The  ineffectiveness  of  these  pharmacological 
agents in both sarcopenia and cachexia underscores the 
need for the identification of new drug targets for the 
treatment of muscle wasting.  
 
Given  the  ineffectiveness  of  targeting  TNFα  directly, 
researchers  began  to  investigate  the  therapeutic 
potential of targeting downstream effectors in the TNFα 
pathway, such as NF-κB and MuRF1. NF-κB inhibition 
therapies  have  shown  potential  for  the  treatment  of 
certain  inflammatory  diseases,  as  well  as  for  the 
treatment of cancer [76-78]. However, given its role as 
a master-regulator of several pathways, prolonged NF-
κB inhibition can result in severe side effects such as 
immunodepression and liver damage [78, 79]. As both 
sarcopenia and cachexia persist over prolonged periods 
of time, any treatment option would need to be viable 
for  extended  periods.  Thus,  targeting  downstream 
effecters of NF-κB-induced muscle wasting may be a 
better therapeutic option. A key mechanism of NF-κB 
dependent muscle-atrophy involves the activation of the 
proteasome degradation pathway by the upregulation of 
the  E3-ligase  MuRF1  [10].  Although  several  studies 
suggest that preventing protein degradation can help to 
attenuate the onset of muscle wasting, knocking out the 
MuRF1 gene does not fully protect mice from NF-κB–
mediated muscle wasting [10, 48], suggesting that NF-
κB induces muscle atrophy by additional mechanisms. 
Therefore, given the ineffectiveness of current treatment 
strategies targeting the TNFα-signaling pathway, there 
is a need to identify novel therapeutic targets. Despite 
several studies clearly implicating iNOS as an important 
effecter  in  the  TNFα/NF-κB  pathway,  to  our 
knowledge,  the  iNOS/NO  pathway  has  never  been 
targeted for the treatment of muscle wasting. 
 
IV  -  INOS/NO:  A  COMMON  EFFECTER 
PATHWAY FOR BOTH SARCOPENIA AND 
CACHEXIA 
 
As described above, two of the main mechanisms by 
which TNFα-induced NF-κB activation triggers muscle 
wasting  are  through  an  upregulation  of  the  ubiquitin-
proteasome  pathway  by  the  increased  expression  of 
MuRF1, as well as through an increase in the expression 
of iNOS, leading to oxidative stress [10, 11, 71, 72]. 
While,  as  described  above,  the  TNFα-mediated 
activation  of  the  proteasome  has  received  a  lot  of 
attention in the recent years, specifically as a potential 
target  for  therapy  against  muscle  wasting,  the  
implication  of  the  iNOS/NO  pathway  remained 
neglected despite several studies linking it to the TNFα-
induced muscle atrophy [11, 12, 14]. iNOS converts L-
arginine  to  citrulline,  releasing  NO  in  the  process. 
Under  certain  conditions,  NO  reacts  with  superoxide 
anions  (O2
-)  to  form  the  toxic  molecule  peroxynitrite 
(ONOO
-), leading to oxidative stress and muscle fiber 
loss  (Figure  3)  [12,  80].  Although  the  detailed 
mechanism of how NO-induced stress leads to muscle 
wasting remains to be elucidated, the production of NO, 
and the subsequent formation of peroxynitrite, has been 
shown  to  decrease  mRNA  levels  of  MyoD—an 
important  transcription  factor  involved  in  myogenesis 
and  maintenance  of  skeletal  muscle  [12,  73].
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Furthermore,  NO  generated  in  response  to  both 
endotoxin and IFN- γ has been found to inhibit general 
translation,  leading  to  decreased  protein  synthesis  in 
muscle fibers [81].  
 
A - The iNOS/NO pathway as a promoter of muscle 
wasting  
 
As  previously  mentioned,  the  role  of  the  ubiquitin-
mediated degradation pathway in sarcopenia is unclear. 
However,  there  is  growing  evidence  for  the  role  of 
iNOS-induced oxidative stress in both sarcopenic and 
cachectic muscle wasting.  Indeed, several studies have 
found an increase in the levels of protein nitration with 
age,  suggesting  an  elevated  level  of  nitric  oxide  and 
peroxynitrite  production  [82-85].  An  in  vivo  study 
evaluating  the  levels  of  iNOS  expression  in  old  and 
young mice found a marked increase in the levels of 
iNOS  protein  in  older  mice  when  compared  to  their 
younger counterparts. This increase in iNOS expression 
was correlated with an age-related increase in caspase-2 
and JNK signaling activity, suggesting that the elevated 
iNOS  expression  may  be  involved  in  age-induced 
skeletal muscle apoptosis [13]. Several in vitro and in 
vivo studies have implicated iNOS in the mechanism of 
cytokine-induced  cachexia  [11,  12,  81].  An 
investigation  of  the  levels  of  iNOS  in  the  skeletal 
muscle  of  COPD  patients  with  low  body  weight—a 
Figure 3: The mechanism of iNOS-induced muscle wasting. TNFα, a key proinflammatory 
cytokine in the induction of muscle wasting, binds to its receptor, activating a signaling pathway 
that culminates in the activation of NF-κB.  NF-κB then enhances the transcription of the iNOS 
transcript, which is subsequently bound by HuR at an ARE in the 3’-UTR and stabilized. This results 
in a dramatic increase in iNOS mRNA levels, resulting in enhanced translation of the iNOS protein. 
iNOS  converts    L-arginine  into  citrulline,  releasing  NO  in  the  process.  Several  NO-dependent 
pathways may be responsible for the induction of muscle wasting. First, NO diffuses out of the cell 
where  it  combines  with  superoxide  (O2
-)  to  form  peroxynitrite  (ONOO
-).  Peroxynitrite  then 
diffuses  back  into  the  cell,  selectively  inhibiting  MyoD,  an  important  myogenic  transcription 
factor, at the post-transcriptional level. Loss of MyoD leads to a reduction in MyHC expression, 
compromising the integrity of the myofibrillar protein complex. Second, NO-production leads to 
the oxidative modification of Jun-D, which, together with myogenin, regulates several key skeletal 
muscle-specific  proteins,  like  CKM.  Finally,  NO-production  may  inhibit  protein  synthesis  by 
inhibiting  mTOR  signaling  and  by  increasing  eIF2α  and  eEF2  phosphorylation,  though  the 
mechanism by which this occurs is uncertain. It is also unclear whether NO causes these last two 
effects directly, or through the formation of peroxynitrite. 
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expression was elevated [47]. Recently, the induction of 
iNOS expression by TNFα was demonstrated in human 
cancer and AIDS patients suffering from cachexia [14]. 
Thus,  given  the  shared  involvement  of  iNOS  in 
mediating  NF-κB  signaling  in  both  cachectic  and 
sarcopenic muscle wasting, any therapy that targets the 
iNOS/NO  pathway  may  prove  to  be  an  effective 
therapeutic strategy in both diseased states.  
 
B - How does iNOS/NO trigger muscle wasting? 
 
In order to target the iNOS/NO pathway, it is essential 
that  the  underlying  mechanism  be  well  understood. 
Recent studies have begun to elucidate the mechanism 
and have confirmed iNOS as a potential target for the 
treatment  of  muscle  wasting.  Although  these  studies 
were carried out in cachectic models of muscle wasting, 
it is reasonable to assume that similar pathways may be 
involved  in  the  molecular  mechanism  of  sarcopenia. 
Indeed,  iNOS  expression  has  been  shown  to  increase 
with  age  and  has  been  correlated  with  age-related 
muscle cell apoptosis [13]. Furthermore, several studies 
have demonstrated elevated levels of protein nitration 
with aging, implying an age-dependent increase in the 
production  of  peroxynitrite  [82-85].  As  described 
below,  peroxynitrite  production  is  a  key  step  in  the 
iNOS-mediated muscle wasting pathway (Figure 3), and 
so together these findings suggest a role for iNOS in 
several age-related pathologies, including sarcopenia.   
 
1.  Inhibition  of  Jun-D  and  loss  of  Muscle  Creatine 
Kinase (CKM) 
 
The  first  observations  connecting  TNFα-induced 
iNOS/NO  production  to  muscle  wasting    was  the 
discovery that TNFα leads to an upregulation of iNOS, 
inducing oxidative stress and a loss of Jun-D activity 
[11].  The  study  found  that  injecting  mice  with  CHO 
cells expressing TNFα -induced muscle wasting and a 
loss  of  CKM  transcriptional  expression.  CKM  is  a 
kinase that synthesizes ATP from phosphocreatine and 
is important for the maintenance of ATP reserves and 
muscle function [86, 87]. Loss of CKM, therefore, is 
detrimental and provides a molecular indication of the 
onset  of  muscle  wasting.  The  decrease  in  CKM 
expression was found to be caused by loss of activity of 
the Jun-D transcription factor. The inhibition of Jun-D 
was  proposed  to  occur  through  the  post-translational 
oxidization  of  its  conserved  cysteine  domain  (KCR). 
The  effects  of  cytokine-induced  oxidative  stress  were 
found to depend on an increased iNOS expression. This 
was  confirmed  by  treatment  with  nitro-L-arginine,  an 
inhibitor of iNOS activity, which was able to prevent 
the symptoms of muscle wasting, indicating that iNOS 
was  likely  the  mediator  of  TNFα-induced  oxidative 
stress [11]. Thus, NO-production by iNOS was shown 
to be involved in the induction of muscle wasting. The 
significance  of  this  was  later  confirmed  in  human 
muscle  wasting  by  Ramamoorthy  et  al.,  who  showed 
that the skeletal muscle of human cachectic patients had 
elevated levels of iNOS mRNA and protein [14]. 
 
2. Loss of MyoD: The Role of Peroxynitrite 
 
In addition to affecting Jun-D, TNFα treatment was also 
found to decrease the mRNA levels of the transcription 
factor MyoD, one of the main promoters of muscle fiber 
formation [73]. Muscle fibers treated with TNFα were 
found to have reduced levels of MyoD protein that was 
associated  with  a  decrease  in  the  mRNA  steady-state 
levels. This inhibition seems to be selective, as other 
important  muscle  transcription  factors  (Myf5  and 
MEF2D) were unaffected. This effect was also observed 
in  fully  differentiated  myotubes,  and  required  the 
addition of IFNγ to potentiate TNFα’s effects. The loss 
of MyoD was dependent on active NF-κB, as indicated 
by the fact that MyoD mRNA decay could be prevented 
by  over-expressing  the NF-κB  repressor  protein  IκBα 
[73].  Loss  of  MyoD  is  known  to  prevent  the 
differentiation  of  myoblasts  (undifferentiated  muscle 
cells) [73, 88, 89], leading to a reduction in the repair 
and  regeneration  capacity  of  muscle  fibers. 
Furthermore,  the  TNFα/IFN-γ-induced  loss  of  MyoD 
has been correlated with the loss of myosin heavy chain 
(MyHC) in differentiated muscle tubes [73]. The results 
were also confirmed in vivo by injecting mice with a 
mixture  of  CHO  cells  expressing  human  TNFα  and 
mouse  IFN-γ  [73].  The  selective  inhibition  of  MyoD 
was  later  found  to  result  in  selective  transcriptional 
down-regulation  of  MyHC  over  other  myofibrillar 
proteins,  such  as  tropomyosin,  troponin,  sarcomeric 
actin,  actinin,  and  myosin  light  chain  [90].  This 
apparent selectivity, both for MyoD and subsequently 
MyHC, suggests that cytokine-induced wasting results 
not from general loss of muscle protein, but from the 
specific targeting of key factors. The loss of MyHC in 
myotubes  likely  compromises  the  integrity  of 
myofilaments and could explain the ability of TNFα to 
reduce  muscle  strength  independently  of  atrophy  and 
protein  loss  [91,  92].  Together,  these  results  showed 
that the loss of MyoD both blocks muscle repair and 
regeneration  and  leads  to  the  degeneration  of  muscle 
fibers.  However,  the  mechanism  by  which  NF-κB 
activation caused this was unknown.  
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MyoD mRNA decay was later found to be caused by 
the upregulation of iNOS by NF-κB, which was further 
enhanced by the stabilizing effects of the human antigen 
protein R (HuR) on the iNOS mRNA transcript (Figure 
3) [12]. Microarray analysis of the expression profile of 
TNFα/IFN-γ  treated  myotubes  showed  that  iNOS 
expression  was  elevated  during  the  first  24  hours  of 
treatment.  The  increase  in  iNOS  mRNA  levels 
correlated  with  a  corresponding  increase  in  iNOS 
protein levels and NO production. However, NO on its 
own  was  found  to  be  insufficient  to  induce  muscle 
wasting, as treatment with an NO-donor, which does not 
produce  peroxynitrite,  did  not  induce  fiber  loss 
(unpublished data) [12]. Instead, it was found that the 
formation of peroxynitrite from the reaction of NO with 
superoxide was responsible for the induction of muscle 
wasting  (Figure  3).  Treatment  with  a  peroxynitrite 
scavenger  prevented  the  loss  of  fibers  induced  by 
cytokine treatment [12]. Thus, loss of MyoD was found 
to  be  caused  by  peroxynitrite  through  an  as  of  yet 
unidentified oxidative stress pathway. 
  
3.  Posttranscriptional  regulation  in  iNOS/NO-induced 
muscle wasting 
 
The transcriptional regulation of iNOS by NF-κB is an 
important part of its cytokine-mediated induction, but it 
does  not  account  for  the  full  fold-increase  in  iNOS 
mRNA expression levels. Cytokine treatment has been 
found to increase the transcription rate of iNOS only 
two- to five-fold, whereas iNOS mRNA levels increase 
up to a 100-fold upon cytokine induction [93, 94]. In 
accordance with this observation, Di Marco et al. found 
that  iNOS  mRNA  in  muscle  cells  is  regulated  post-
transcriptionally at the level of RNA stability, and that 
this  regulation  partially  accounts  for  the  increase  in 
iNOS mRNA steady state levels [12]. Previous studies 
had  identified  an  A/U  rich  element  (ARE)  in  the  3’-
UTR  of  the  human  iNOS  transcript  [95].  AREs  are 
known to destabilize transcripts, resulting in their rapid 
turnover  [96-98].  The  RNA-binding  protein  HuR  is 
known  to  bind  to  these  AREs,  regulating  mRNA 
expression through cellular turnover and nuclear export 
[99-103]. Often, HuR binding stabilizes the transcript, 
promoting  its  expression  by  extending  its  half-life.  A 
previous study of the interaction of HuR with human 
iNOS  had  shown  that  HuR  binding  stabilized  the 
otherwise labile iNOS mRNA [95]. These results were 
confirmed in an in vitro model of cachexia, indicating 
the  importance  of  HuR-mediated  regulation  of  iNOS 
during cytokine-induced muscle wasting [12].  
 
4. Inhibition of Protein Synthesis 
 
In addition to the above effects, NO has also been found 
to  induce  the  phosphorylation  of  the  eukaryotic 
translation initiation factor 2 (eIF2α) and to inhibit the 
mTOR  pathway,  leading  to  the  inhibition  of  general 
translation [81, 104]. In a study of the effects of NO on 
protein  translation,  Kim  et  al.  found  that  both  NO 
donors  and  increased  iNOS  expression  were  able  to 
reduce  protein  translation  in  a  variety  of  cell  types 
[104].  In  RAW264.7  murine  macrophage  cells,  this 
reduction  in  protein  synthesis  is  caused  by  the 
phosphorylation of eIF2α, leading to the inhibition of 
the 80S ribosomal complex [104]. Further studies are 
needed  to  confirm  whether  this  mechanism  occurs  in 
muscle cells and to determine whether it plays a role in 
NO-dependent muscle wasting. In another study, Frost 
et al. showed that cytokine-induced expression of iNOS 
in mouse muscle cells led to an inhibition of the mTOR 
pathway,  causing  a  decreased  phosphorylation  of  the 
downstream targets 4E-BP1 and ribosomal protein S6. 
The decreased phosphorylation of these factors, in turn, 
caused a reduction in general translation.  In addition, 
eEF2 phosphorylation was found to increase, suggesting 
that NO blocks protein translation both at the level of 
initiation  and  elongation  [81].  They  found  that  this 
inhibition  of  general  translation  could  be  reversed  by 
treatment with an iNOS inhibitor, confirming the role of 
iNOS in this cytokine-induced mechanism [81]. These 
studies  demonstrate  that  prolonged  exposure  to  high 
doses of NO, as is found in the muscle wasting state, 
can inhibit general protein synthesis. However, in vitro 
and in vivo studies are needed to confirm a role for this 
pathway  in  the  progression  of  muscle  wasting. 
Furthermore, it is unclear whether the effects of NO are 
caused directly or by the production of peroxynitrite, as 
is seen in NO-mediated MyoD inhibition [12].    
 
5. Future Goals: Expanding the Role of Peroxynitrite 
 
Together, these findings suggest a mechanism whereby 
the TNFα signaling pathway stimulates the expression 
of iNOS, both by transcriptional activation by NF-κB 
and post-transcriptional stabilization by HuR, leading to 
the production of NO and ultimately peroxynitrite. The 
peroxynitrite  then  induces  oxidative  stress,  targeting 
pathways  important  for  muscle  differentiation  and 
maintenance,  which  results  in  muscle  fiber 
degeneration.  In  addition,  fiber  degeneration  may  be 
further  enhanced  by  the  apparent  NO-mediated 
inhibition  of  Jun-D  binding  activity  and  protein 
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 synthesis (Figure 3). Despite these new insights into the 
underlying  mechanism  of  the  iNOS/NO  pathway, 
several  details  need  to  be  elucidated.  One  important 
question  remaining  is  how  peroxynitrite  specifically 
targets  only  certain  myogenic  factors.  It  has  been 
observed  that  nitrosylation  by  peroxynitrite  proceeds 
slowly  with  most  biological  molecules  and  that 
peroxynitrite  is  therefore  a  selective  oxidant. 
Nitrosylation  is  believed  to  be  an  important  post-
translational  modification  involved  in  multiple human 
diseases [87, 105], and may prove to be the mechanism 
by  which  peroxynitrite  induces  muscle  atrophy.  This 
apparent  selectivity  might  also  explain  how 
peroxynitrite  specifically  targets  MyoD  over  other 
myogenic  transcription  factors.  Furthermore,  it  is 
possible that peroxynitrite may be responsible for other 
observed  pro-cachectic  effects  of  NO.  It  has  been 
shown  that  treatment  with  antioxidants  is  able  to 
prevent TNFα-induced reduction in specific tension in 
isolated, permeabilized mouse muscle, confirming the 
importance of oxidative modification in the mechanism 
of TNFα-induced wasting [92]. It  is possible that  the 
peroxynitrite-mediated loss of MyoD, and subsequently 
MyHC, is partially responsible for this loss of specific 
tension,  and  so  treatment  with  antioxidants  may 
alleviate  TNFα-induced  muscle  weakening  by 
scavenging  superoxide  and  preventing  peroxynitrite 
formation.  It  is  also  unclear  whether  peroxynitrite  is 
involved in NO-mediated inhibition of Jun-D binding 
activity  and  protein  translation.  More  investigation  is 
needed  to  fully  understand  the  mechanism  by  which 
peroxynitrite-induced  oxidative  stress  specifically 
targets certain vital muscle proteins and triggers muscle 
atrophy.  
 
C  -  Potential  Targets  in  the  iNOS/NO  pathway  to 
combat muscle wasting 
 
Several pharmacological compounds currently exist for 
the treatment of sarcopenia and cachexia [21, 23, 48, 
49].  However,  none  of  them  have  been  approved  for 
widespread  use.  Although  some  of  these  treatments 
have shown some promising results, none of them were 
successfully able to fully reverse the effects of muscle 
wasting. Consequently, there is a need to identify new 
targets for the treatment of cachexia that might show 
equal or greater therapeutic potential. 
 
Several  possibilities  exist  for  targeting  the  iNOS/NO 
pathway  for  the  treatment  of  muscle  wasting.  For 
example, small molecular inhibitors of the iNOS protein 
could, conceivably, be able to prevent the detrimental 
effects  of  cytokine-induced  NO  production.  In  their 
murine  model  of  cachexia,  Buck  et  al.  were  able  to 
demonstrate  that  feeding  mice  injected  with  TNFα-
producing CHO cells with the iNOS-inhibitor nitro-L-
arginine was able to attenuate the effects of cachexia 
[11].  Besides  targeting  iNOS  directly,  one  could  also 
attempt  to  inhibit  its  action  by  scavenging  the 
peroxynitrite,  the  oxidative  agent  effecter  of  iNOS. 
Indeed,  treatment  with  the  peroxynitrite  scavenger 
FeTPPS  has  been  shown  to  prevent  muscle  fiber 
atrophy and iNOS-mediated MyoD loss [12]. One might 
also be able to inhibit peroxynitrite by targeting ROS 
generation in muscle, thereby preventing the formation 
of  peroxynitrite.  Furthermore,  ROS  have  been 
implicated in several models of aging and age-related 
disease, and so inhibiting their production may prove to 
particularly effective in combating age-related  muscle 
wasting  (sarcopenia)  [106-108].  NADPH  oxidase  is 
believed to be a significance source of ROS in skeletal 
muscle [109, 110], and so inhibiting NADPH oxidase 
may  help  attenuate  muscle  wasting  symptoms.  More 
intensive investigation is required to fully explore the 
potential  of  these  options  in  the  clinical  treatment  of 
muscle wasting. 
 
V - CONCLUSION 
 
While  mounting  evidence  supports  the  implication  of 
the  iNOS/NO  pathway  in  muscle  wasting,  many 
questions  remain  unanswered.  It  is  still  unknown 
whether  NO  or  a  product  of  the  iNOS/NO  pathway 
compromises  muscle  integrity  by  affecting  the 
expression of other key components, besides Jun-D and 
MyoD,  involved  in  muscle  fibers  formation, 
maintenance  or  both.    Moreover,  the  way  by  which 
peroxynitrite leads to the degradation of MyoD mRNA 
is  still  elusive.  In  addition,  it  is  unclear  whether 
peroxynitrite plays a role in NO-mediated inhibition of 
protein  synthesis  and  Jun-D  activity.  Further 
investigation  is  required  to  more  clearly  establish  the 
role of peroxynitrite in  muscle wasting. Nevertheless, 
the ability of peroxynitrite scavengers and antioxidants 
to  prevent  muscle  wasting  symptoms  suggests  that 
targeting peroxynitrite may be an efficacious treatment 
option.  Furthermore,  given  the  role  of  iNOS/NO  in 
other important physiological pathways, such as normal 
muscle  repair  and  the  innate  immune  response  [111, 
112],  targeting  peroxynitrite,  either  directly  or  by 
inhibition of ROS generation, may prove to be a more 
desirable treatment as it would allow for inhibition of 
NO-mediated  atrophic  effects,  without  affecting  NO-
mediated beneficial effects. In the end, sarcopenia and 
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 cachexia are multifactoral syndromes, and it is unlikely 
that  any  one  treatment  will  provide  a  miracle  cure. 
Instead,  a  combination  of  therapies  targeting  multiple 
effectors  will  likely  be  necessary.  To  this  end, 
identifying other direct-effectors of muscle wasting as 
targets for the development of inhibition therapies is an 
important  first  step  towards  the  search  for  a cure  for 
muscle wasting syndrome. 
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